June 06, 2019

Pharmaceutical Company Resolves FCA Suit Over Drug Price Fixing

A Heritage Pharmaceuticals, a generic drug manufacturer, recently settled  an FCA suit involving allegations that Heritage paid and received remuneration from other drug manufacturers and engaged in a scheme to inflate and fix prices for generic drugs. In addition to the $7 million civil settlement, the company entered into a three-year deferred prosecution agreement with the DOJ’s Antitrust Division and agreed to pay a $250,000 criminal penalty.